Anebulo Pharmaceuticals, Inc.
ANEB
$1.14
$0.065.56%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -2.46M | -2.20M | -1.35M | -1.65M | -2.72M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | 59.70K | 59.70K | 59.70K | 59.70K | 31.80K |
| Total Other Non-Cash Items | 564.30K | 286.90K | 177.20K | 151.60K | 219.30K |
| Change in Net Operating Assets | 433.30K | 164.10K | -939.90K | -55.20K | 652.60K |
| Cash from Operations | -1.41M | -1.69M | -2.05M | -1.50M | -1.81M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 15.00M | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 0.00 | 0.00 | -62.40K |
| Cash from Financing | 15.00M | -- | 0.00 | 0.00 | -62.40K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 13.59M | -1.69M | -2.05M | -1.50M | -1.88M |